Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × Dasatinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12 Leukemia, Myeloid, Chronic-Phase 7 Leukemia, Myeloid, Acute 7 Leukemia, Myeloid, Accelerated Phase 7 Leukemia 6 Blast Crisis 6 Neoplasms 5 Multiple Myeloma 5 Burkitt Lymphoma 5 Waldenstrom Macroglobulinemia 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Non-Hodgkin 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Hodgkin Disease 4 Sezary Syndrome 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Myelodysplastic Syndromes 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, Extranodal NK-T-Cell 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Large Granular Lymphocytic 3 Leukemia, Hairy Cell 3

Interventions

Nivolumab 6 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Paclitaxel 4 Docetaxel 4 Pemetrexed 3 Ipilimumab 3 Erlotinib Hydrochloride 3 Carboplatin 3 ARRY-334543 3 apatinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1 tislelizumab 1 tilsotolimod 1 sargramostim 1 regorafenib 1 ralimetinib 1 prexasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00895128 2015-07-13

Study of Erlotinib in Combination With Dasatinib

M.D. Anderson Cancer Center

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡